Liver Experts Look to Earlier MASH Detection
Researchers at The Liver Meeting 2026 in Denver highlighted earlier disease detection and expanding treatment options as developments to watch.
Updated on Nov. 13, 2026 in Healthcare

Researchers and clinicians at The Liver Meeting 2026, held by the American Association for the Study of Liver Diseases in Denver, Colorado, identified earlier detection of liver disease and expanded MASH treatment options as developments likely to shape liver care in the coming year. Currently there are 2 approved drugs for MASH.
Why it matters
Many patients have overlapping conditions, such as hepatitis B combined with metabolic disease, making noninvasive tests for risk stratification increasingly important. Rising obesity and diabetes mean few patients have only a single liver disease.
Only 2 drugs are currently approved for MASH, according to conference presenters, and both are cited as the baseline for expanding options. What remains unresolved is how quickly new therapies and noninvasive diagnostic tests will move from research into routine clinical practice.
The players
American Association for the Study of Liver Diseases
A professional medical society that organizes The Liver Meeting and promotes research and clinical care for liver disease.
Jörn M. Schattenberg
A professor at Saarland University Medical Center in Germany who is a researcher in liver disease.
Zobair M. Younossi
The chairman of the Global NASH Council and a researcher focused on fatty liver disease.
Snehal Chaudhari
An assistant professor of biochemistry at the University of Wisconsin-Madison who researches liver disease biology.
The details
Researchers presented phase 2b data on efinopegdutide, and experts discussed serum proteomics and cell-free DNA methylation as approaches to detect MASH earlier. Future blood tests measuring amino acids and other small molecules may offer a snapshot of disease in the liver and other organs.
Timeline
2026: The Liver Meeting is held in Denver, Colorado.
Coming year: Shifts in liver care from earlier detection and new treatments are expected.
Health Landscape
The findings reported at the American Association for the Study of Liver Diseases' Liver Meeting reflect a field shifting from a single approved MASH drug toward a broader set of therapies and detection tools. Rising obesity and diabetes rates are driving this change, as they increasingly leave patients with overlapping liver conditions.
Patients with fatty liver disease may see more treatment options and noninvasive tests in the coming years, though the extraction does not specify timing. Individuals with overlapping metabolic conditions could benefit from earlier risk assessment once these tools reach clinical use.
The takeaway
Earlier detection and a wider range of treatments could change how clinicians manage liver disease, especially as obesity and diabetes increasingly affect the same patients. Staying informed about new diagnostic tests may help patients and caregivers discuss options with their doctors.
Further reading
Explore more on Healthcare to see how medical research and treatment developments are shaping the industry.
Source note: This article includes information reported by Ajmc.



